drugset / Trial / NCT02941679

Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients

NCT02941679 ↗

Phase 3 Unknown 252 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A phase 3 study to evaluate efficacy and safety of HCP1202

Timeline

Start
2016-10
Primary completion
2018-02
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator HCP0910 Unknown — —
Subject HCP1202 Unknown — —
Comparator HGP1011 Unknown — —